Anebulo Pharmaceuticals, Inc. (ANEB)

US — Healthcare Sector
Peers: ADAG  ACRV  ANAB  MLYS  AVTE  OPT  ANTX    PMVP  MOLN 

Automate Your Wheel Strategy on ANEB

With Tiblio's Option Bot, you can configure your own wheel strategy including ANEB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ANEB
  • Rev/Share 0.0
  • Book/Share 0.3277
  • PB 3.2044
  • Debt/Equity 0.0
  • CurrentRatio 32.2934
  • ROIC -0.6062

 

  • MktCap 43138935.0
  • FreeCF/Share -0.1643
  • PFCF -6.3904
  • PE -5.6098
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.9011

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Anebulo Pharmaceuticals, Inc. (ANEB)

  • IPO Date 2021-05-07
  • Website https://www.anebulo.com
  • Industry Biotechnology
  • CEO Mr. Richard Anthony Cunningham
  • Employees 2
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.